ORPHA:97287
Bronchial neuroendocrine tumor
Also known as: Bronchial NET
Publications
184
71.4th percentile
Trials
1
Interventional, condition-specific
Researchers
1,232
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare neuroendocrine neoplasm characterized by origin from pulmonary neuroendocrine cells and ranging from low-grade typical carcinoid and intermediate-grade atypical carcinoid to high-grade large-cell neuroendocrine carcinoma and small-cell carcinoma. Two thirds of the tumors are located in the major bronchi, with a predilection for the right lung, in particular the middle lobe. Most patients with central bronchial tumors present with hemoptysis, cough, recurrent pulmonary infections, fever, chest discomfort, and unilateral wheezing, while peripheral carcinoids are usually discovered only incidentally. Carcinoid syndrome or Cushing syndrome are very rare. The tumors may be part of multiple endocrine neoplasia type 1.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
Additional Mondo synonyms (7)
bronchial NET · bronchus NET · bronchus neuroendocrine neoplasm · bronchus neuroendocrine tumor · bronchus neuroendocrine tumor, well differentiated, low or intermediate grade · bronchus neuroendocrine tumour · neuroendocrine neoplasm of bronchus
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
184 matched papers (133 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
1 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
184
184 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
184 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
133 in the last 10 years · high confidence · 71.4th percentile (publications denominator)
Phrase hits: 184 · MeSH hits: 0
Who's working on it?
1,232
Distinct author names in 184 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Faggiano A6 papers · 2025
Endocrinology, Department of Experimental Medicine, "Sapienza", University of Rome, Rome, Italy. antiongiulio.faggiano@uniroma1.it.
Papers in Europe PMC - 02Colao A5 papers · 2025
Endocrinology, Department of Clinical Medicine and Surgery, "Federico II" University of Napoli, Napoli, Italy.
Papers in Europe PMC - 03de Herder WW5 papers · 2025
Department of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC and Erasmus Cancer Institute, Rotterdam, The Netherlands.
Papers in Europe PMC - 04Hofland J5 papers · 2025
Department of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC and Erasmus Cancer Institute, Rotterdam, The Netherlands.
Papers in Europe PMC - 05Brabander T4 papers · 2025
Department of Radiology & Nuclear Medicine, ENETS Center of Excellence, Erasmus MC and Erasmus Cancer Institute, Rotterdam, The Netherlands.
Papers in Europe PMC - 06Liu Y4 papers · 2023
Department of Radiation Oncology, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China.
Papers in Europe PMC - 07Bodei L3 papers · 2020
Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Papers in Europe PMC - 08Capdevila J3 papers · 2022
Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Papers in Europe PMC - 09Caplin M3 papers · 2026
Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; 1 currently recruiting in our sample.
Data as of 27 July 2026
1 interventional trial — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 76.8th percentile).
high confidence · 76.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05636618·RECRUITING·Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Conditions: Neuroendocrine Tumors Unresectable · Neuroendocrine Tumor Metastatic · Gastroenteropancreatic Neuroendocrine Tumor · Bronchial Neuroendocrine Tumor·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Bronchial neuroendocrine tumor" OR "Bronchial NET" OR "bronchus NET" OR "bronchus neuroendocrine neoplasm" OR "bronchus neuroendocrine tumor" OR "bronchus neuroendocrine tumor, well differentiated, low or intermediate grade" OR "bronchus neuroendocrine tumour" OR "neuroendocrine neoplasm of bronchus" OR "neuroendocrine neoplasm of the bronchus"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Bronchial neuroendocrine tumor" OR "Bronchial NET" OR "bronchus NET" OR "bronchus neuroendocrine neoplasm" OR "bronchus neuroendocrine tumor" OR "bronchus neuroendocrine tumor, well differentiated, low or intermediate grade" OR "bronchus neuroendocrine tumour" OR "neuroendocrine neoplasm of bronchus" OR "neuroendocrine neoplasm of the bronchus"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T05:08:09.581Z